Search

A patent application titled "Network Topology For Insulin Pump Systems" has been published online. The application describes systems, devices, and methods for insulin pump systems that allow a durable controller device to securely communicate with a mobile computing device and various peripheral devices using a common wireless communication standard. The durable controller can manage the delivery of insulin locally, make dosing determinations, and control the operation of the insulin pump. The use of a single chipset and interface for communication can reduce costs, minimize power consumption, and increase battery life. The patent application also mentions the use of a mobile application and a cloud service to store and communicate patient information. [Extracted from the article]

A patent has been issued for systems, devices, and methods for integrating an analyte data reader and medication delivery device. The patent, assigned to Abbott Diabetes Care Inc., aims to address the need for an integrated device that can monitor analyte levels and administer medication, such as insulin, for individuals with diabetes. The integrated device has a small form factor, similar to an insulin pen, and can wirelessly communicate with a sensor control device worn on the body. The patent also includes methods for preventing medication injection during adverse conditions and obtaining recent analyte level data. [Extracted from the article]

Becton Dickinson and Company has been issued a patent for a medical device that delivers drug therapy to individuals with diabetes. The device utilizes capacitive coupling communication and energy harvesting, and includes a microcontroller, pump mechanism, transceiver, and power supply system. It communicates with a host device through a personal area network and is powered by energy harvested from the user's body. This patent application highlights the use of proinsulin, a peptide hormone, in the device, which could potentially enhance healthcare and medical treatment options. [Extracted from the article]

Tandem Diabetes Care Inc. has been granted a patent for a sleep mode in their automated insulin delivery system. This sleep mode adjusts the glucose target and range to accommodate the specific needs during sleep. The patent outlines different methods for transitioning to sleep mode, such as considering the time since the last insulin dose, using algorithms to predict low glucose levels, and estimating the amount of insulin in the user's body. These methods aim to improve glucose control without increasing the risk of hypoglycemia. The patent also describes an ambulatory infusion pump system that delivers insulin based on glucose levels from a continuous glucose monitor. The system includes a processor that calculates insulin doses to maintain glucose levels within a target range. If necessary, the system can adjust the target range immediately or gradually based on the time since the last insulin delivery. The patent was filed by Alexandra Elena Constantin and published in April 2024. [Extracted from the article]

A recent study conducted by the Department of General Surgery explored the use of flap capillary blood glucose monitoring as a predictor of flap survival in limberg flap surgery for pilonidal sinus. The researchers found that monitoring capillary blood glucose levels in the postoperative period can help identify flaps at risk and initiate early goal-directed therapy to improve flap survival. This simple and inexpensive technique can be used alongside routine clinical evaluation for monitoring limberg flaps. The study provides valuable insights into improving the outcomes of pilonidal sinus surgery. [Extracted from the article]

This document provides information about a clinical trial, NCT06384911, that aims to investigate the effectiveness of a financial incentives program called InvesT1D in improving diabetes self-management in adolescents with type 1 diabetes. The trial will randomly assign participants to either usual care or the financial incentives program and compare changes in glucose levels and person-reported outcomes between the two groups. The trial will also assess various outcome measures, including time in range, hemoglobin A1c levels, and quality of life. The goal is to understand if financial incentives can help adolescents with their daily self-management of diabetes. The trial is being conducted by Seattle Children's Hospital in collaboration with Harvard Pilgrim Health Care and is expected to be completed by February 2028. [Extracted from the article]

A patent has been issued to Abbott Diabetes Care Inc. for systems and methods for using insulin information for meal indication. The invention aims to provide a glucose report based on large amounts of glucose data, showing patterns and analyses of the glucose history of a patient to aid in treatment considerations. The system includes a processor, non-volatile memory, and display to analyze and visually present glucose data and analytics. The method involves storing glucose data, collecting insulin timing information, identifying meal-related glucose data, performing pattern analysis, and providing treatment recommendations based on the number of rise or fall patterns detected. [Extracted from the article]

A patent application has been submitted for the invention of a system that automatically detects when a meal has not been properly bolused for individuals with diabetes. The system utilizes continuous glucose monitoring (CGM) data to determine if a meal has been consumed within a specific time period and if a bolus has been delivered. If no bolus has been delivered and the CGM data exceeds a certain threshold, the system provides a reminder to the user to deliver the bolus. The invention aims to improve diabetes therapy by ensuring proper medication delivery. [Extracted from the article]

Medtronic MiniMed Inc. has been issued a patent for methods, systems, and devices for calibrating and optimizing glucose sensors and sensor output. The patent describes a method for externally calibrating a glucose sensor to measure glucose levels in the body. It addresses the limitations of current calibration methods and aims to provide more accurate and reliable glucose monitoring. The patent also includes details about the sensor design and predictive models used in the calibration process. The patent was filed by Peter Ajemba and assigned to Medtronic MiniMed Inc. [Extracted from the article]

A patent has been issued to DexCom Inc. for a time-averaged basal rate optimizer. The patent describes a method for optimizing a basal rate profile for continuous insulin therapy. The method involves periodically updating the basal rate profile based on a retrospective analysis of continuous glucose sensor data and adjusting the profile in response to real-time glucose sensor data indicating hyperglycemia or hypoglycemia. This technology aims to improve the accuracy and effectiveness of insulin dosing for individuals with diabetes. [Extracted from the article]

A patent has been issued to Bigfoot Biomedical Inc. for insulin injection assistance systems, methods, and devices. The patent aims to address the challenges faced by individuals with diabetes in determining appropriate doses of insulin. The invention includes a recommendation system that analyzes glucose data and timing information to provide adjustment recommendations for insulin delivery. The system can be used with manual insulin delivery devices and incorporates user-friendly interfaces to simplify therapy management. The patent also mentions the potential for the system to be adapted for the delivery of other medications and the treatment of other diseases. [Extracted from the article]

A patent has been issued to Medtronic MiniMed Inc. for systems that improve the breathability of medical devices, such as glucose sensors or continuous glucose monitors. These systems transfer or direct moisture from the medical device into the surrounding environment, preventing discomfort or irritation to the user. The patent describes various embodiments of the medical device, including a coupling system with adhesive members that have cut-outs to direct moisture away from the device. The patent provides detailed information and claims about the design and functionality of these systems. [Extracted from the article]

Researchers from the University of Hong Kong have developed a coin-sized, fully integrated, and minimally invasive continuous glucose monitoring (CGM) system based on organic electrochemical transistors (OECTs). CGMs are crucial for closed-loop diabetes management, and this new system offers enhanced antinoise ability, reliability, and wearability. The CGM consists of an OECT for improved signal-to-noise ratio, a microneedle array for subcutaneous glucose sampling, and a soft hydrogel to stabilize the skin-device interface. Compared to conventional CGMs, this system provides high antinoise ability, tunable sensitivity and resolution, and comfort wearability, enabling personalized glucose sensing for precision diabetes healthcare. [Extracted from the article]

This document provides information about a clinical trial study, NCT06382246, that aims to investigate the effects of exercise snacks on individuals with type 2 diabetes. The study is currently in the recruitment phase and plans to enroll 40 participants. The primary completion date for data collection is July 15, 2025. The study has specific eligibility criteria, including age, diagnosis of type 2 diabetes, current level of physical activity, and access to technology. The study does not accept healthy volunteers and is open to all genders. The responsible party for the study is Jonathan Little from the University of British Columbia, with collaboration from McMaster University. Contact details for the primary investigator are provided. [Extracted from the article]

This document provides information about a clinical trial, NCT06382259, that aims to investigate the acute impact of low-intensity movement breaks on glycemic control in physically inactive individuals with type 2 diabetes. Participants will wear a continuous glucose monitor and undergo two 48-hour experimental conditions, one with exercise breaks and one without. The exercise breaks will involve stretching and mobility-based exercises, and meals will be standardized. The trial aims to assess glycemic responses using various outcome measures. The study is not yet recruiting participants and is estimated to be completed by July 15, 2025. The eligibility criteria include being aged 30-75 years old, having a physician-diagnosed type 2 diabetes, and currently participating in less than 150 minutes of moderate-to-vigorous intensity aerobic exercise per week. The study will be conducted at McMaster University, with Jonathan P Little, PhD as the primary contact. [Extracted from the article]

This document provides information about a research study on the effects of driving on individuals with type 1 diabetes. The study aims to assess the frequency of hypoglycemia during driving periods and other related outcomes. The study will involve participants who use an insulin pump and continuous glucose monitoring. Data will be collected and analyzed anonymously to ensure privacy and confidentiality. The study is not yet recruiting participants and is expected to be completed by May 2026. [Extracted from the article]

Suntory Holdings Limited has submitted a patent application for a blood sugar constitution determination device. The device uses a questionnaire to determine a user's blood sugar constitution type and provides personalized advice based on the type. It includes a storage unit for question information, an output unit to present the questions, an acceptance unit to collect user answers, a processing unit to determine the blood sugar constitution type, and an information output unit to provide output information. The device may also incorporate machine learning to improve accuracy and make it easier for users to understand their blood sugar constitution type. [Extracted from the article]

A recent report discusses research on diabetes mellitus management, specifically focusing on type 2 diabetes. The study aims to improve the health of type 2 diabetes patients by developing a favorable lifestyle using an AI-assisted continuous glucose monitoring (CGM) digital system. The researchers trained a machine learning model on CGM sensor data to predict blood glucose levels and used time series analysis and forecasting techniques. The study also incorporated an AI solution for food recognition to adjust the patients' diet based on the predicted results and nutrient content. The goal is to help patients manage their diabetes and bring their HbA1c levels within the normal range. [Extracted from the article]

The patent application titled "Systems And Methods For Automatically Assisting Patients" discusses the use of data collection platforms in healthcare to collect and analyze healthcare-related data. These platforms can be used with medical devices to deliver therapies and monitor patient conditions. The application also proposes a triage system to prioritize patient interventions based on their condition and interaction with the system. The goal is to improve the management and assistance provided to remotely managed patient populations. The method involves identifying issues affecting patient satisfaction and providing educational material and troubleshooting recommendations to improve outcomes. [Extracted from the article]

A patent application has been submitted for a system and method that aims to improve the management and assistance provided to remotely managed patient populations. The system combines data collection with therapy, such as an implanted neuromodulator or an insulin pump, to determine a triage tier for intervention by a clinician or device representative. The method involves delivering therapy, assessing the patient's condition, receiving patient interaction, and using both the condition and interaction to assign a priority ranking for intervention. The patent application provides detailed information on the different components and processes involved in the system. [Extracted from the article]

This document provides information about a clinical trial at the University of Missouri, Kansas City, that aims to evaluate a behavioral treatment program for adult patients with type 2 diabetes. The study will assess if the program, which includes diabetes coaching, financial rewards, and continuous glucose monitoring, improves adherence to a diabetes treatment plan and blood sugar management. Participants will wear a continuous glucose monitor and receive diabetes coaching and financial rewards, while the control group will only wear the monitor and continue with their usual treatment. The trial is expected to be completed by December 31, 2024. [Extracted from the article]

A report from Case Western Reserve University discusses the findings of a needs assessment conducted by the Ohio Cardiovascular and Diabetes Health Collaborative (Cardi-OH). The collaborative aims to improve cardiovascular and diabetes health outcomes and eliminate disparities in Ohio's Medicaid population. The needs assessment surveyed both grant-funded and non-grant-funded members of Cardi-OH and identified high-priority clinical topics, screening practices, policy changes, and preferences for the dissemination of evidence-based best practices. The top topics identified included lifestyle prescriptions, mental health and cardiovascular disease, family-focused interventions, and adverse childhood events. The report emphasizes the importance of identifying high-priority educational topics and preferred delivery modalities to ensure the practicality and usefulness of resources for healthcare providers. [Extracted from the article]

A study conducted by Kaiser Permanente in South San Francisco aimed to determine if continuous glucose monitor (CGM) metrics could provide advance warning of emergency department visits or hospitalizations for hypoglycemic or hyperglycemic events. The study found that while several CGM metrics were strongly associated with the risk of dysglycemic events, none had good discrimination to reliably provide actionable advance warning. The research suggests that patients who do not use their CGM device may be at elevated risk of adverse outcomes. However, further interventions are needed to improve the predictive value of CGM metrics. [Extracted from the article]

A patent application by Becton Dickinson and Company has been made available online for a cannula insertion detection device. The device aims to ensure that a cannula, catheter, or probe reaches the proper insertion depth and can detect if it is oriented at an angle. The invention includes an insertion monitor with electrical contacts or mechanical posts that provide indication of the cannula insertion status. The device also includes an alert mechanism to notify the user if the cannula is incorrectly inserted. [Extracted from the article]

A patent has been issued to Abbott Diabetes Care Inc. for systems, devices, and methods for managing glucose levels. The patent describes the use of user interface input mechanisms with haptic feedback capabilities to improve functionality and privacy for patients. The glucose management devices include a user interface controlled by a processor, with a touch screen display that visually displays a graph of glucose levels and provides haptic feedback in response to user input. The patent also mentions the use of insulin infusion pumps and continuous glucose monitoring devices in conjunction with the user interface. [Extracted from the article]

A patent application has been published online for a system that continuously monitors glucose levels in diabetic individuals. The system includes a sensor, transmitter, and data processing module, and displays the data graphically on a mobile device. The display can show patterns in the data and relationships between insulin, glucose, and events. This technology has the potential to improve glucose monitoring for diabetics. The article discusses the application of software for data visualization in the field of health and medicine, specifically for analyzing peptide hormone data. [Extracted from the article]

New research from Universitas Muhammadiyah Kudus discusses the impact of physical exercise on blood sugar levels in individuals with diabetes mellitus. The study found that regular physical walking exercises significantly reduced blood sugar levels. The research suggests that physical exercise can be incorporated into chronic disease management programs and can benefit individuals with diabetes, non-communicable diseases, and elderly patients. This information may be useful for individuals looking to manage their blood sugar levels through exercise. [Extracted from the article]

A recent study conducted at SRM University explores the use of photoacoustic spectroscopy (PAS) as a potential method for non-invasive detection of blood glucose levels. The researchers propose a polynomial kernel-based ridge regression approach to accurately detect random blood glucose using PAS. They also investigate the impact of BMI on blood glucose regulation. The study develops a non-invasive portable device that collects the photoacoustic signal from a finger using a pulsed laser source. The accuracy of the device was assessed using various metrics and was found to outperform previous approaches. This research provides a new and more accurate method for monitoring random blood glucose levels. [Extracted from the article]

A recent study conducted by the University of Messina in Italy explores the development of an artificial pancreas for individuals with type 1 diabetes. The researchers highlight the challenges involved in designing and developing such a device, including the need for an accurate mathematical model of the patient's physiology. The study provides a comprehensive overview of recent advances in modeling biological processes and developing nonlinear control strategies for the artificial pancreas. The researchers also emphasize the importance of real-time parameter estimation, effective uncertainty management, and in-depth clinical studies to assess the efficacy and safety of the device. The study concludes by discussing the potential for control techniques that address individual patient conditions and enable personalized diabetes management. [Extracted from the article]

A patent has been issued to DexCom Inc. for a sensor interposer employing castellated through-vias. The interposer is a component of wearable biosensors, such as continuous glucose monitors, that are inserted into a wearer's skin. The interposer mechanically secures the sensor wire and provides electrical contacts to different electrodes on the wire. The use of castellated through-vias helps reduce heat transfer during manufacturing processes and enables the formation of guard rings for electrical isolation. The patent provides detailed claims and descriptions of the sensor interposer. [Extracted from the article]

A patent has been issued to Medtronic MiniMed Inc. for a combined device that includes an analyte sensor and an infusion set hub. The device is designed to manage the lack of insulin in individuals with diabetes by delivering insulin subcutaneously. The analyte sensor monitors glucose levels in the interstitial fluid and can transmit data to a monitor or recording device. The device is modular, allowing for individual replacement of either the analyte sensor or the infusion set hub. The patent provides detailed descriptions and claims for the device. [Extracted from the article]

A patent application titled "Fluid Infusion Systems" has been published online by the US Patent and Trademark Office. The application describes a portable fluid infusion device, such as an insulin pump, that is more convenient and easier to use for users. The device includes features such as a planar battery, a user interface without a display, and the integration of an infusion set with a physiological characteristic sensor. The application also discusses wearable fluid infusion devices and fluid infusion systems that can be adhesively coupled to a user's anatomy. The invention aims to improve the convenience, usability, and cost-effectiveness of fluid infusion devices. [Extracted from the article]

A clinical trial, NCT06347783, is being conducted to examine the impact of insulin pumps on sleep in children with type 1 diabetes and their caregivers. The trial aims to determine whether insulin pumps have a positive, negative, or neutral effect on sleep quality, as well as explore the connection between insulin pumps, sleep, and overnight blood sugar control. Participants will be asked to complete questionnaires, surveys, wear a FitBit during sleep, and maintain daily sleep diaries. The trial is observational and will last for four months. This document provides information about a research study that is not yet recruiting participants. The study aims to investigate the relationship between sleep and type 1 diabetes in children and adolescents. The study will include participants aged 6-18 who have been diagnosed with type 1 diabetes for at least 6 months and are currently receiving treatment through multiple daily injections of insulin. Participants will be required to have smartphone access and download the FitBit application. The study will collect data through surveys and a daily sleep diary. The estimated completion date for the study is December 15, 2024. [Extracted from the article]

A recent study conducted at the University of Michigan evaluated the feasibility and performance of continuous glucose monitoring (CGM) to guide computerized insulin infusion therapy in the cardiovascular intensive care unit. The study found that CGM, when combined with periodic point-of-care blood glucose tests, was accurate and convenient for both nurses and patients. The results suggest that adopting CGM in postoperative care could improve workflow, enhance health outcomes, and be cost-effective. Further research is needed to confirm these findings. [Extracted from the article]

A recent study conducted by researchers at the University of Southern California (USC) explored the impact of 8-hour time-limited eating (TLE) on sleep quality in adolescents with obesity. The study found that an 8-hour TLE approach did not negatively affect sleep quality or efficiency when compared to a prolonged eating window. The researchers suggest that further investigation is needed in larger randomized trials to fully understand the potential effects of TLE on sleep. This research has been peer-reviewed and published in the Journal of Clinical Sleep Medicine. [Extracted from the article]

A patent application has been submitted for an apparatus and methods to maintain and clean medical devices. The invention aims to address concerns related to blood-borne pathogen disease transmission, particularly in scenarios where components of a continuous glucose monitor (CGM) may be used by multiple users. The invention includes an enclosure for the CGM, with covers and adhesives to secure the device and prevent contamination. The patent application also describes a method for reprocessing reusable electronic medical devices and a protective case with a lock to deter device removal. [Extracted from the article]

A patent application titled "Methods For Reduction of Battery Usage In Ambulatory Infusion Pumps" has been published online. The application discusses the need for conserving battery power in ambulatory infusion pumps, which are used for delivering fluids in medical treatments. The invention proposes systems and methods for conserving battery life by limiting data transfers between the infusion pump and other devices, such as smartphones and cloud storage services. The patent application provides detailed descriptions and claims for various embodiments of the invention. [Extracted from the article]

A recent report discusses research findings on the accuracy of continuous glucose monitoring (CGM) devices in pediatric diabetic ketoacidosis (DKA) admissions. The study compared point-of-care glucose values to personal Dexcom G6 sensor data during hospitalizations. The results showed that CGM accuracy is similar between DKA and non-DKA admissions, as well as during severe DKA and IV insulin administration. However, further research is needed to determine the feasibility of implementing CGM in hospitals. This study was conducted by researchers at the University of Colorado Anschutz Medical Campus and was supported by the NIH National Institute of Diabetes & Digestive & Kidney Diseases and the Juvenile Diabetes Research Foundation. [Extracted from the article]

A clinical trial, NCT06334484, has been launched to evaluate the effect of an advanced hybrid closed loop system on adjunctive continuous glucose monitoring metrics in individuals with type 1 diabetes mellitus. The trial aims to assess the glycemic improvement expressed through standardized metrics such as time spent within optimal glucose range, time below target glucose range, and time above target glucose range. The advanced hybrid closed loop system combines insulin pump infusion and real-time continuous glucose monitoring data to optimize glycemic control. The trial is currently in the recruitment phase and is expected to be completed by March 2026. [Extracted from the article]

Becton Dickinson and Company has been issued a patent for systems, apparatuses, and methods for medical device communication with remote devices. The patent addresses the increasing demand for wearable medical devices and the need for enhanced security in wireless communication. The invention involves the use of different wireless communication protocols to securely exchange information between the medical device and a controlling device, while also allowing for less secure communication with other devices. The patent provides solutions for ensuring the privacy and security of medical device control signals and patient information. [Extracted from the article]

A patent application titled "Systems And Methods For Updating A Medical Device" has been published online. The inventors discuss the limitations of current glucose meters and propose methods and systems for updating medical devices. The application describes establishing a connection between a peripheral device and a medical device, identifying data and software associated with the peripheral device, and updating the medical device based on this information. The medical device could include glucose meters, continuous glucose monitoring devices, oximeters, pulse oximeters, temperature sensors, respirometers, heart rate monitors, electrocardiogram monitors, or blood pressure monitors. The patent application also includes claims related to an analyte monitoring system and the detection and analysis of events for trend data. [Extracted from the article]

DexCom Inc. has been issued a patent for systems and methods that enhance the visualization and interpretation of health data for continuous glucose monitoring. The system includes a sensor, transmitter, and data processing module that continuously monitor glucose levels and display graphical representations of the data on mobile devices. The system can analyze the data based on various factors and provide user support tools such as trend graphs and colored displays. This technology aims to improve the understanding of health data for individuals using continuous glucose monitoring devices. [Extracted from the article]

The document provides information about a clinical trial, NCT06333184, which is currently recruiting participants in the United Kingdom. The trial aims to investigate the effects of different types of carbohydrates on physiological responses, specifically focusing on the glycemic response to a commercially available fruit smoothie. Participants will consume seven different test drinks in a randomized, crossover design, and blood samples will be taken to measure the glycemic response. The data from this trial will provide insights into how factors such as the food matrix, ingestion rate, dose ingested, and fiber content can affect the glycemic response to a fruit smoothie, as well as how the measurement method may impact interpretations. The trial is being conducted by Javier Gonzalez from the University of Bath, and the data will be openly shared on the University of Bath Research Data Archive. [Extracted from the article]

A recent report published by researchers at the Institut fur Diabetes-Technologie in Ulm, Germany, highlights the importance of usability testing in the development process of diabetes technologies. The study focused on a continuous glucose monitoring (CGM) device and assessed its safety and effectiveness for users. The researchers found that the prototype device had usability issues, particularly related to the handling of reusable detectors and the instructions for use. The study emphasizes the need for structured usability testing before finalizing a product, and suggests improvements such as restructuring the instructions and providing additional training for users. [Extracted from the article]

A recent report from the University of Miami Miller School of Medicine highlights the importance of blood glucose monitoring in the management of Type 1 diabetes (T1D). Continuous glucose monitoring (CGM) devices have shown effectiveness in optimizing glycemic control and improving the quality of life for individuals with T1D. The development of innovative blood glucose monitoring devices, particularly those using electrochemical sensors, has the potential to enhance glycemic control and prevent T1D-related complications. The report emphasizes the rigorous approval process regulated by the Food and Drug Administration (FDA) for these devices. Overall, the research suggests that non-invasive blood glucose monitoring devices hold promise for improving the health outcomes and life expectancy of individuals with T1D. [Extracted from the article]

A recent report from Rome, Italy discusses the relationship between diabetes and mental health. Researchers have been using continuous glucose monitoring (CGM) to explore the association between glucose-related metrics and psychological aspects. The study found that higher levels of sadness/depression correlated with lower %TIR (time in range) and higher %TAR (time above range). The research suggests that %TIR may play a positive role in reducing depressive feelings in individuals with diabetes, while depressive feelings may have a negative impact on achieving desirable CGM outcomes. The study also highlights the potential role of glycemic variability, particularly hyperglycemia, in the expression of depressive and sad feelings. [Extracted from the article]

This document provides information about a clinical trial, NCT06319300, that aims to evaluate the use of an artificial intelligence-assisted insulin dose adjustment system in hospitalized patients with Type 2 diabetes. The trial will compare the outcomes of patients whose insulin doses are adjusted by the AI system versus those whose doses are adjusted by doctors. The trial is not yet recruiting participants and is expected to be completed by May 2026. The document also includes eligibility criteria for participants and administrative information about the trial. Keywords associated with the trial include hospitals, Type 2 diabetes, machine learning, and clinical research. [Extracted from the article]

Researchers from the Department of Electronics and Communication Engineering have developed an Internet of Things (IoT) enabled wearable blood glucose monitoring system to improve diabetes care and enhance quality of life. The system utilizes a wearable device integrated with the TTGOT-ESP32 IoT platform and a red and near-infrared (R-NIR) spectral range for blood glucose measurement. The device provides optimal comfort for patients and has an accuracy rate of 98.82% after 10 hours of fasting and 98.04% after 2 hours of breakfast. The research contributes to the field of IoT-based healthcare solutions and has the potential to transform diabetes management and healthcare delivery. [Extracted from the article]

A patent application titled "Recyclable Device For Deploying Transcutaneous Sensors And Related Technology" has been published online. The inventor, Ellis Garai, filed the application on September 7, 2022, and it became available on March 7, 2024. The patent application describes a deployment device for transcutaneous sensors used in monitoring blood glucose levels in diabetic patients. The device aims to improve the convenience and sustainability of deploying transcutaneous devices for diabetes management. It includes a housing, plunger, frame, cap, spring, carrier, and stop, and allows for easy connection and removal of the transcutaneous device. [Extracted from the article]

A recent study published in the Journal of Biomedical Optics presents a new methodology for estimating blood glucose levels (BGLs) using near-infrared (NIR) measurements. The research team derived a blood glucose level index from NIR formulas and found that the phase delay between the oscillating components of oxyhemoglobin and deoxyhemoglobin signals is closely related to metabolism. The team conducted experiments using a commercial smartwatch and a custom smartphone holder, and the results showed a close correlation between the metabolic index and BGLs. While clinical tests are pending, the researchers believe their approach could lead to portable and accessible BGL monitoring devices in the future. [Extracted from the article]